Entinostat, also known as SNDX-275 and MS-275, is a benzamide histone deacetylase inhibitor undergoing clinical trials for treatment of various cancers. Entinostat inhibits class I HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM, respectively. ==Clinical trials== There is an ongoing phase II trial studying the effect of entinostat on Hodgkin`s ....
Found on
http://en.wikipedia.org/wiki/Entinostat
A substance being studied in the treatment of several types of cancer. It blocks enzymes needed for cell division and may kill cancer cells. It is a type of histone deacetylase (HDAC) inhibitor. Also called HDAC inhibitor SNDX-275 and SNDX-275.
Found on
http://www.cancer.gov/dictionary?expand=E
No exact match found.
